05.10.2016 • News

Syngenta Completes Plant Expansions

(c) Syngenta
(c) Syngenta

Swiss agrochemicals producer Syngenta has completed capacity expansions at key production sites in Brazil and Switzerland. Altogether, the company has invested $240 million in the projects, which include a new fungicide plant in Paulínia, São Paulo, and an expanded corn seed factory in Formosa, Goiás, both in Brazil. It has also widened output capability for S-Metolachlor in Kaisten, Switzerland.

The Paulínia formulation plant for the fungicide sold under the Elatus trademark is claimed to be the first in Latin America to make use of the peptite technology, which Syngenta said results in water-soluble granules that combine the properties of liquid use with the convenience and easy transportable advantage of a dry, solid product. This is said to improve transportation of the ingredients to the plant tissue, ensuring rapid and systemic protection of the crop.

Syngenta’s sales of Elatus in Latin America exceeded $400 million in 2015. The company said the fungicide “provides outstanding potency against soybean rust and provides long lasting control and increased yield benefits for the grower.” At the Formosa site, production at the corn seed plant has been quadrupled to raise its production capacity to 1.6 million bags of corn per year from 400,000 t/y.

Syngenta sad the investment in Kaisten has enabled a “significant production capacity expansion” for S-Metolachlor, a leading herbicide used in many of its brands. It said the herbicide “has proven to be a critical tool in managing weeds that are increasingly difficult to control in a number of crops, notably corn and soybean.”

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.